MedPath

se of intravenous acetylsalicylic acid (‘Aspirin’) as a novel antidote for human paraquat poisoning- can it reduce the 70% mortality rate and oxidative stress?

Phase 2
Conditions
Paraquat self poisoning
Registration Number
SLCTR/2009/001
Lead Sponsor
Welcome Trust and NHMRC through SACTRC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow up complete
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Paraquat self poisoning presenting within 24 hours and a positive urine dithionite test

Exclusion Criteria

Age under 14 years pregnanacy presenting after 24 hours known aspirin allergy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measure of oxidative markers as outlined before 3. Plasma and EBC 4-Hydroxy-2-nonenal and F2?-isoprostane concentrations (GC/MS) 4. Plasma and EBC proteins CC16 and SP-D (Assay kits) 5. EBC Hydrogen peroxide concentrations (Assay kit) 6. EBC Thiobarbituric Acid Reactive Substances (TBARS) (spectrophotometric assay) 7. EBC Proteomic 8. Urinary F2?-isoprostane and prostacyclin levels<br> []<br>
Secondary Outcome Measures
NameTimeMethod
Death []<br>
© Copyright 2025. All Rights Reserved by MedPath